Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system

Nature

Volumn 436, Issue 7050, 2005, Pages 568-572

  Sengupta, Shiladitya ^a   Eavarone, David ^a   Capila, Ishan ^a   Zhao, Ganlin ^a   Watson, Nicki ^b   Kiziltepe, Tanyel ^a   Sasisekharan, Ram ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD VESSELS; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DRUG THERAPY; GROWTH KINETICS; NANOSTRUCTURED MATERIALS; TUMORS;

BLOOD VESSEL GROWTH; LONG-TERM SHUTDOWN; NEOVASCULATURE; TUMOUR CELLS;

CELLS;

ANTINEOPLASTIC AGENT; COMBRETASTATIN; DOXORUBICIN; LIPID; NANOPARTICLE; ANGIOGENESIS INHIBITOR; BIBENZYL DERIVATIVE; STILBENE DERIVATIVE;

CANCER;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CANCER THERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENDOTHELIUM CELL; LEWIS CARCINOMA; MALE; MELANOMA; MOUSE; NANOCELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR CELL; TUMOR MODEL; ANIMAL; COCULTURE; DRUG COMBINATION; EXPERIMENTAL MELANOMA; HUMAN; METHODOLOGY; NANOTECHNOLOGY; NEOPLASM; PATHOLOGY; TIME; TISSUE DISTRIBUTION; VASCULARIZATION;

ANIMALIA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIBENZYLS; CARCINOMA, LEWIS LUNG; COCULTURE TECHNIQUES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; NANOTECHNOLOGY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STILBENES; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 23144456813     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03794     Document Type: Article

References (21)

1. Kerbel, R. S. & Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nature Rev. Cancer 4, 423-436 (2004).
2. Semenza, G. L. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J. Clin. Invest. 106, 809-812 (2000).
3. Tran, J. et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad. Sci. USA 99, 4349-4354 (2002).
4. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J. & Kerbel, R. S. Effect of p53 status on tumour response to antiangiogenic therapy. Science 295, 1526-1528 (2002).
5. Blagosklonny, M. V. Antiangiogenic therapy and tumour progression. Cancer Cell 5, 13-17 (2004).
6. Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361 (2003).
7. Rofstad, E. K. et al. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res. 62, 1847-1853 (2002).
8. Kieran, M. W., Folkman, J. & Heymach, J. Angiogenesis inhibitors and hypoxia. Nature Med. 9, 1104 (2003).
9. Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727-739 (2002).
10. Chabner, B. A., et al. Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th edn (McGraw-Hill, 1996).
11. Tozer, G. M., Kanthou, C., Parkins, C. S. & Hill, S. A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. 83, 21-38 (2002).
12. Miklos, A. G., Lyman, M. D., Freed, L. E. & Langer, R. Wetting of poly(L-lactic acid) and poly(D-lactic-co-glycolic acid) foams for tissue culture. Biomaterials 15, 55-58 (1994).
13. Yoo, H. S., Oh, J. E., Lee, K. H. & Park, T. G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res. 16, 1114-1118 (1999).
14. Sengupta, S., Kiziltepe, T. & Sasisekharan, R. A dual-colour fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules. FASEB J. 18, 1565-1567 (2004).
15. Jain, R. K. Normalizing tumour vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 7, 987-989 (2001).
16. Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice. J. Clin. Invest. 105, 1045-1047 (2000).
17. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Drug Discov. 2, 750-763 (2002).
18. Yuan, F. et al. Vascular permeability in a human tumour xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752-3756 (1995).
19. Tong, R. T. et al. Vascular normalization by vascular endothelial growth facor receptor-2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736 (2004).
20. Arap, W. et al. Steps toward mapping the human vasculature by phage display. Nature Med. 8, 121-127 (2002).
21. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).